TIRZEPATIDE, A DUAL GIP AND GLP-1 RECEPTOR AGONIST, INCREASES INSULIN SENSITIVITY AND IMPROVES PANCREATIC BETA-CELL FUNCTION IN TYPE 2 DIABETES

被引：0
|
作者：
Pirro, V. [1 ]
Nikooienejad, A. [1 ]
Lin, Y. [1 ]
Willency, J. [1 ]
Wilson, J. [1 ]
Duffin, K. [1 ]
Robins, D. [1 ]
Milicevic, Z. [1 ]
Haupt, A. [1 ]
Thomas, M. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P232 / #49
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [41] The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist
    Urva, Shweta
    Nauck, Michael A.
    Coskun, Tamer
    Cui, Xuewei
    Haupt, Axel
    Benson, Charles
    Loghin, Corina
    DIABETES, 2019, 68
  • [42] The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist
    Urva, S.
    Nauck, M. A.
    Coskun, T.
    Cui, X.
    Haupt, A.
    Benson, C. T.
    Loghin, C.
    DIABETOLOGIA, 2019, 62 : S58 - S58
  • [43] Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
    Lee, Clare J.
    Mao, Huzhang
    Thieu, Vivian T.
    Lando, Laura Fernandez
    Thomas, Melissa K.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (05)
  • [44] Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
    Stefanou, Maria-Ioanna
    Theodorou, Aikaterini
    Malhotra, Konark
    Aguiar de Sousa, Diana
    Katan, Mira
    Palaiodimou, Lina
    Katsanos, Aristeidis H.
    Koutroulou, Ioanna
    Lambadiari, Vaia
    Lemmens, Robin
    Giannopoulos, Sotirios
    Alexandrov, Andrei, V
    Siasos, Gerasimos
    Tsivgoulis, Georgios
    EUROPEAN STROKE JOURNAL, 2024, 9 (03) : 530 - 539
  • [45] Efficacy and safety of once weekly tirzepatide, a dual GIP/GLP-1 receptor agonist versus placebo as monotherapy in people with type 2 diabetes (SURPASS-1)
    Rosenstock, J.
    Wysham, C.
    Frias, J. P.
    Kaneko, S.
    Lee, C. J.
    Lando, L. Fernandez
    Mao, H.
    Cui, X.
    Thieu, V. T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 246 - 246
  • [46] Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
    Pirro, Valentina
    Roth, Kenneth D.
    Lin, Yanzhu
    Willency, Jill A.
    Milligan, Paul L.
    Wilson, Jonathan M.
    Ruotolo, Giacomo
    Haupt, Axel
    Newgard, Christopher B.
    Duffin, Kevin L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02): : 363 - 378
  • [47] Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 382 : 2074
  • [48] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Michael A. Nauck
    David A. D‘Alessio
    Cardiovascular Diabetology, 21
  • [49] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Nauck, Michael A.
    D'Alessio, David A.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [50] Tirzepatide as Monotherapy Improved Markers of Beta-Cell Function and Insulin Sensitivity in People with Type 2 Diabetes (SURPASS-1)
    Lee, Clare
    Mao, Huzhang
    Thieu, Vivian
    Thomas, Melissa K.
    DIABETES, 2022, 71
12345